I-Liraglutide ye-Anti-Diabetics yoLawulo lweSwekile yeGazi CAS NO.204656-20-2
Iinkcukacha zeMveliso
| CAS | 204656-20-2 | Ifomula yeemolekyuli | C172H265N43O51 |
| Ubunzima beMolekyuli | 3751.20 | Imbonakalo | Mhlophe |
| Imeko yoGcino | Ukumelana nokukhanya, i-2-8 degree | Iphakheji | I-aluminium foil bag / vial |
| Ubunyulu | ≥98% | Ezothutho | Cold Chain kunye nokuhanjiswa kogcino olupholileyo |
Izithako zeLiraglutide
Isithako esisebenzayo:
I-Liraglutide (i-analog ye-glucagon-like peptide-1 (GLP-1) eveliswe yigwele ngetekhnoloji yokuhlanganiswa kwakhona kofuzo).
Igama leMchiza:
Arg34Lys26-(N-e-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Ezinye izithako:
I-Disodium Hydrogen Phosphate Dihydrate, iPropylene Glycol, i-Hydrochloric Acid kunye / okanye i-Sodium Hydroxide (njenge-pH Adjusters Kuphela), i-Phenol, kunye naManzi okuTofa.
Isicelo
Uhlobo lwe-2 yeswekile
ILiraglutide iphucula ulawulo lweswekile yegazi. Iyanciphisa i-hyperglycemia enxulumene nokutya (kwiiyure ezingama-24 emva kokulawulwa) ngokunyusa i-insulin secretion (kuphela) xa ifunwa ngokunyusa amanqanaba eglucose, ukulibazisa ukukhutshwa kwesisu, kunye nokucinezela i-prandial glucagon secretion.
Ilungele izigulane ezineswekile yegazi engekalawuleki kakuhle emva kwedosi ephezulu enyanyezelweyo ye-metformin okanye i-sulfonylureas yodwa. Isetyenziswa ngokudibeneyo ne-metformin okanye i-sulfonylureas.
Isebenza ngendlela exhomekeke kwi-glucose, oku kuthetha ukuba iya kuvuselela ukukhutshwa kwe-insulin kuphela xa amanqanaba eglucose yegazi ephezulu kunesiqhelo, ukukhusela "ukugqithiswa". Ngenxa yoko, kubonisa umngcipheko ongenakulinganiswa we-hypoglycemia.
Inamandla okuthintela i-apoptosis kunye nokuvuselela ukuvuselelwa kweeseli ze-beta (ezibonwa kwizifundo zezilwanyana).
Yehlisa umdla wokutya kwaye inqande ukufumana ubunzima bomzimba, njengoko kubonisiwe kuphononongo lwentloko ukuya entloko ngokuchasene ne-glimepiride.
Isenzo se-Pharmacological
I-Liraglutide yi-analog ye-GLP-1 ene-97% yokulandelelana kwe-homology kwi-GLP-1 yomntu, enokuthi ibophe kwaye ivule i-GLP-1 receptor. I-GLP-1 receptor ijolise kwi-GLP-1 yemveli, ihomoni ye-incretin engapheliyo ekhuthaza ukukhuselwa kwe-insulin exhomekeke kwi-insulin kwiiseli ze-pancreatic β. Ngokungafaniyo ne-GLP-1 yemveli, iiprofayili ze-pharmacokinetic kunye ne-pharmacodynamic ze-liraglutide ebantwini zilungele irejimeni yokudosa kube kanye yonke imihla. Emva kwesitofu se-subcutaneous, indlela yayo yesenzo sexesha elide ibandakanya: ukuzibandakanya ngokwakho okunciphisa ukufunxa; ukubophelela kwi-albumin; Uzinzo oluphezulu lwe-enzyme kwaye ngaloo ndlela ixesha elide lesiqingatha sobomi be-plasma.
Umsebenzi we-liraglutide ulungelelwaniswa yintsebenziswano ethile kunye ne-GLP-1 receptor, ekhokelela ekunyukeni kwe-cyclic adenosine monophosphate (cAMP). I-Liraglutide ivuselela ukukhuselwa kwe-insulin ngendlela exhomekeke kwi-glucose, ngelixa inciphisa ukukhutshwa kweglucagon ngokugqithisileyo ngendlela exhomekeke kwi-glucose.
Ngoko ke, xa i-glucose yegazi iphakama, i-insulin secretion ivuselelwe, ngelixa i-glucagon secretion ivinjelwe. Ngokwahlukileyo, i-liraglutide inciphisa ukukhuselwa kwe-insulin ngexesha le-hypoglycemia ngaphandle kokuchaphazela ukukhutshwa kweglucagon. Inkqubo ye-hypoglycemic ye-liraglutide ikwabandakanya ukongezwa kwexesha lokukhupha isisu. I-Liraglutide yehlisa ubunzima bomzimba kunye nobunzima bomzimba ngokunciphisa indlala kunye nokuthatha amandla.
